

Individualized Care in Radiation Oncology

www.rt-safe.com



MedTech Company



THE PROBLEM: Lack of personalized treatment verification solution for patients with brain tumors.

MARKET SIZE: €6B, roughly 4M patients with brain tumor cancer, per annum, globally.



OUR VISION: Improve quality of life and increase life expectancy of radiotherapy patients, while bringing overall cost of treatments down.

RTsafe SOLUTION: first ever personalized treatment verification in radiotherapy using patient specific (bespoke) phantoms. A patented solution for efficient and safe, individualized radiotherapy.

RTsafe TARGET MARKET: Capture 5% of global brain radiotherapy treatments in 5 years.

REGULATORY STATUS: 510 (k) FDA clearance

Patent granted in Europe. Pending in many other countries.

DISTRIBUTION CHANNELS: Outsourcing local distributors.

SEEKING TO RAISE: €2M, on €35M valuation, with sales breakeven at €2.4M in 24months.

Cancer patients risk during radiotherapy treatment

GLOBAL STATS

- 18M new cancer cases per year → 23M per year by 2030 (*World Health Organization*).
- Out of these, 20%-40%, develop brain metastases.


UNMET NEEDS IN BRAIN RADIO THERAPY

- **Minimize complications.** A few mm error can significantly deteriorate the quality of life of the patient or be fatal.
- **Maximize treatment efficiency.** A preferred solution in brain cancer cases, where many highly dosed and precisely focused radiation beams target tumors.




An augmented solution for cancer patients

with high barriers to entry



RTsafe's innovative technology



RTsafe introduces individualized medicine to radiotherapy treatment:

- World's first patient-specific Quality Assurance solution
- Separate phantom for each separate patient
- Reduces risk of collateral damage during treatment
- Enhances and ensures treatment efficiency




TREATMENT

Brain
Radiotherapy +

SOLUTION

PRODUCT


RTsafe's Personalized *PseudoPatient*TM



SERVICE

Treatment Verification Service

BENEFITS



A tested and verified solution



PUBLICATIONS

Indicative Recent

In collaboration with **LMU University of Munich, Germany_ 2018**

Proton Therapy Range Verification

In collaboration with **UT Health San Antonio, MD Anderson, Texas, USA_2018_2017**

Highlighting the added value of Brainlab and ELEKTA brain radiosurgery.

In collaboration with **Thomas Jefferson University, Philadelphia, USA_2016**

Verifying the safety and efficiency of the first patient treated in USA with a novel radiosurgery technique.

Publications list at: <https://rt-safe.com/publications/>

ACCREDITATION

Indicatively

By **UCLA**

<https://www.youtube.com/watch?v=LaFt68tY1wY&t=627s>

See RTsafe solutions working in practice for UCLA machine quality assurance purposes.

(old company logo – video created in Aug 2017)

By **ELEKTA**

Signed MOU for collaboration

<https://www.elekta.com/meta/press-all.html?id=F9D4DBAA895B6B51>

By **The Hellenic Initiative**

<https://www.thehellenicinitiative.org/videos/>

5th annual gala video

By **MIT**

1st prize winner of the MIT EF GR 2015 competition


Indicative end-users




Stellar competitive advantages



RTsafe offers a personalized solution VS competitors' generic one



Multiple benefits for...



Healthcare System: RTsafe brings overall treatment costs down for the cancer Eco-system:

- Creating an advantage for payers such as insurance companies, under-written by life insurance companies.

The Journey



<https://www.elekta.com/meta/press-all.html?id=F9D4DBAA895B6B51>

<https://rt-safe.com/news/article/36/rt-safe-receives-510k-fda-clearance-personalized-radiotherapy-verification/>